课题基金 / 基金详情

T-CELL LINE FROM AN APLASTIC ANEMIA PATIENT THAT PRODUCES HIGH LEVELS OF HTLV-II

T-CELL LINE FROM AN APLASTIC ANEMIA PATIENT THAT PRODUCES HIGH LEVELS OF HTLV-II
来自再生障碍性贫血患者的 T 细胞系,可产生高水平的 HTLV-II
批准号:
3804866
负责人:
M RUTA
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

M RUTA的其他基金

相似基金

相关文献

中文摘要
翻译
Epstein-Barr相关性再生障碍性贫血患者的外周血白细胞 建立IL-2依赖的细胞培养体系(JR)。JR 细胞是CD4阳性的,并产生类似HTLV-II的病毒,由 电子显微镜、逆转录酶分析、聚合酶链式反应和Southern杂交 分析。基因组DNA的PCR和Southern blotting分析都给出了 HTLV II特异性探针检测结果为阳性,而HTLV检测为阴性 我和HIV探头。JR病毒是有传染性的,这取决于 新感染的T细胞和B细胞中的病毒DNA。然而,我们一直在 用JR病毒转化脐带血未获成功 该病毒可能是弱的,也可能是不转化的。患者JR的血清也是 ELISA和免疫印迹检测HTLV I/II抗体均为阳性,但 艾滋病毒抗体阴性。这项研究表明HTLV II可能在 在再生障碍性贫血中的作用。再生障碍性贫血患者的其他血清是 正在分析HTLV II的抗体。JR细胞系代表 只有第四个HTLV II感染细胞系来自一名患者。 手稿正在准备中。
英文摘要
Peripheral leukocytes from an Epstein-Barr associated aplastic anemia patient were used to establish an IL-2 dependent cell culture (JR). JR cells are CD4 positive and produce an HTLV-II like virus as determined by electron microscopy, reverse transcriptase analysis, PCR and Southern blot analysis. Both PCR and Southern blotting analysis of genomic DNA gave positive results using HTLV II specific probes but were negative with HTLV I and HIV probes. The JR virus is infectious determined by the presence of viral DNA in newly infected T and B cell lines. However, we have been unsuccessful in transforming cord blood cells with JR virus suggesting that the virus may be weakly or non transforming. Sera from patient JR was also positive for antibodies to HTLV I/II by ELISA and western blot, but was negative for HIV antibodies. This study suggests that HTLV II may play a role in aplastic anemia. Additional sera from aplastic anemia patients are being analyzed for antibodies to HTLV II. The JR cell lines represents only the fourth HTLV II infected cell line derived from a patient. Manuscript in preparation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHARACTERIZATION OF A NOVEL HTLV-II CELL LINE
HTLV-II ELISA AND WESTERN BLOTS
FGF RECEPTOR EXPRESSION IN TUMORS
SEROLOGIC MARKERS OF HTLV-I/II INFECTION
海外基金